Previous 10 | Next 10 |
Replimune ([[REPL]] +1.2%) has dosed the first patient in a Phase 1, open-label, dose-escalation and expansion clinical trial of gene therapy RP3 both alone and in combination with anti-PD-1 therapy, for advanced solid tumors.The immune-gene therapy to treat advanced solid tumors is...
WOBURN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced it has dosed the first patient in a Phase 1, open-label, dose-escalation and expan...
Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers. The company has nearly half a billion dollars in cash. Catalysts are a bit distant, and insiders do not seem to be buying their own company. For further details see: Replimune: In...
Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...
Small caps finally record a new high after two years and turn positive for the year. Vaccine progress is raising expectations of a more robust and durable economic recovery in 2021, driving a rotation into lagging segments and economically sensitive sectors. Small caps can witness...
Investors looking for stocks that can triple their money found what they were looking for in the biotech industry quite a few times this year. Some of those rockets are going to keep climbing, but most will eventually fizzle out. Surface Oncology (NASDAQ: SURF) and Replimmune ...
WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will host investor meetings at the...
WOBURN, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that the posters being presented at the Society for Immunotherapy of Cancer (SITC) ...
Replimune Group (REPL): FQ2 GAAP EPS of -$0.46 misses by $0.02.Cash, cash equivalents and short-term investments of $244.6M.Press Release For further details see: Replimune Group EPS misses by $0.02
RP1 : Updated deep and durable response data with Opdivo ® in CSCC and anti- PD1 failed melanoma continue to support ongoing registration-directed development RP2 : Single agent d eep and durable responses in ...
News, Short Squeeze, Breakout and More Instantly...
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Gold...
2024-06-07 07:00:05 ET Robert Burns from H.C. Wainwright issued a price target of $17.00 for REPL on 2024-06-07 06:07:00. The adjusted price target was set to $17.00. At the time of the announcement, REPL was trading at $7.11. The overall price target consensus is at $26...